Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01507012
Other study ID # 28AI1
Secondary ID
Status Completed
Phase N/A
First received September 20, 2011
Last updated January 9, 2012
Start date September 2010
Est. completion date February 2011

Study information

Verified date January 2012
Source Northumbria University
Contact n/a
Is FDA regulated No
Health authority New Zealand: Health and Disability Ethics Committees
Study type Interventional

Clinical Trial Summary

Polyphenols, compounds found at high levels in berry fruit, have been shown to have health promoting benefits through various mechanisms both in vivo and in vitro. These benefits include antioxidant activity, anti-inflammatory properties, and monoamine oxidase (MAO) inhibition. This study aims to expand on the extremely promising animal data in the literature, and our own pilot study results, to investigate whether drinks containing berry fruit can improve cognitive performance and mood in healthy human participants.

Our central hypothesis is that fruit extracts can reduce the breakdown of neurotransmitters such as dopamine and serotonin. This reduction in breakdown could therefore increase the levels of these neurotransmitters and convey some benefits in regards to mood and cognitive function. The investigators will assess the pharmacokinetic activity of berry fruit extracts on MAO activity to test this hypothesis.

A second hypothesis is that berryfruit polyphenols may alter circulating levels of glucose that may in turn affect cognitive performance and mood.

A prior study carried out by Plant & Food Research through collaboration with the University of Northumbria, UK, found promising results after acutely supplementing participants with a berry fruit based drink. This study aims to use the results from the previous study to assess in depth the effect of berry fruit drinks on human behaviour.


Description:

This project will investigate the acute effects on human cognitive behaviour and mood of a single consumption of 2 berryfruit drinks (with balanced polyphenol content) versus a placebo. Drinks are matched for taste, sugar content and appearance. Drinks contain natural berry fruit grown and juiced or extracted in New Zealand under food-safe conditions.

The study will follow a double-blind, counterbalanced, placebo controlled, repeated measures design with 36 healthy participants aged between 18 and 30 completing 3 study day sessions as well as one training/screening visit (four visits in total). On one occasion participants will receive a placebo, on another berryfruit drink 1, and on another berryfruit drink 2. Study days will be spaced one week apart to accommodate a wash out period. Both berryfruit drinks will be made to include 500mg of polyphenols/60kg of body weight. Sucralose (artificial sweetener) will be added to make the drinks palatable. Participants will be screened for any intolerance or allergies to the drinks during the training/screening session.

Psychometric tasks and mood scales will be measured using the Computerised Mental Performance Assessment System (COMPASS), a purpose designed software application for the flexible delivery of randomly generated parallel versions of standard and novel cognitive assessment tasks that has previously been shown to be sensitive to nutritional interventions and was used in the prior study conducted at Northumbria University. The cognitive assessment battery will include: Bond-Lader mood scales, visual analogue mood scales, 7 repetitions of Digital Vigilance, Stroop, Rapid Visual Information Processing and Mental Fatigue Visual Analogue scales. This is followed by a logical reasoning task and a final set of the Bond-Lader mood scales.

Baseline cognitive testing will involve one repetition of the cognitive assessment battery (Bond-Lader mood scales, Visual Analogue scales, Digital Vigilance, Stroop and RVIP followed by a second set of Visual Analogue scales).

On all 3 testing days participants will arrive at the lab in the morning (8:30 am), after an overnight fast, and firstly give a 10 mL venous blood sample taken by a trained phlebotomist. Participants will then have their blood glucose measured via a finger prick and heart rate/blood pressure (autonomic measures) measured using an automated digital blood pressure monitor. Participants will then complete one repetition of the COMPASS computerised cognitive assessment battery (baseline). Participants will then be orally supplemented with treatment in the form of a single serve juice drink.

After a 60 minute absorption period, autonomic measurements and a second blood glucose reading will be taken. Participants will then complete the COMPASS assessment. After completion of the assessment, a third set of autonomic measurements will be immediately taken along with a third blood glucose reading and a second 10 mL venous blood sample.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date February 2011
Est. primary completion date January 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- MMale/female,

- Healthy Age 18-35 years old

- Non smoker

- Proficient in English

- Not taking any herbal or prescription medications

- Not pregnant or seeking to become pregnant, BMI < 30kg/m2

Exclusion Criteria:

- Tobacco user,

- pregnant or seeking to become pregnant,

- currently taking recreational over the counter/prescription medication (excluding the contraceptive pill) and/or dietary/herbal supplements.

- Food allergies or sensitivities that are relevant to the study,

- learning difficulties,

- ADHD,

- dyslexia,

- migraines or

- any gastric problems

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Berry Polyphenols

Placebo
Placebo control containing sugar and artificial flavouring.

Locations

Country Name City State
New Zealand The New Zealand Institute for Plant & Food Research Ltd Auckland

Sponsors (2)

Lead Sponsor Collaborator
Northumbria University The New Zealand Institute for Plant and Food Research

Country where clinical trial is conducted

New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Attention and vigilance Attention and vigilance will be measured at baseline ad then 1 hour post supplementation of the study treatment. at baseline the digit vigilance task, stroop task and RVIP task will be completed. One hour post supplementation of the study treatment, 7 sets of digit vigilance, stroop and RVIP will be completed. The outcome measures will be treated as change from baseline scores. baseline, 1 hour post dose then incrementally every 10 minutes for 70 minutes. No
Primary Change from baseline blood platelet monoamine oxidase-B activity Baseline and 150 minutes post dose No
Primary Change from baseline visual analogue scale fatigue baseline, 1 hour post dose then incrementally every 10 minutes for 70 minutes. No
Primary Change from baseline blood glucose mmol/L Baseline, 60 minutes post dose and 150 minutes post dose No
Primary Change from baseline blood plasma anthocyanin levels Baseline and 150 minutes post supplementation No
Primary Change from baseline visual analogue scale difficulty baseline, 1 hour post dose then incrementally every 10 minutes for 70 minutes. No
Primary Change from baseline Bond Lader mood scales Baseline, 60 minutes and 1 hour 50 minutes post dose No
Primary Change from baseline diastolic blood pressure Baseline, 60 minutes and 150 minutes No
Primary Change from baseline systolic blood pressure Baseline, 60 minutes and 150 minutes post supplementation No
Primary Change from baseline logical reasoning Baseline and 150 minutes post supplementation No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1